ESPERION | REACHING GOALS

Esperion Q3 2022 Earnings Presentation

November 1, 2022



Forward-looking Statements & Disclosures

This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the impact of the ongoing COVID-19 pandemic on our business, revenues, results of operations and financial condition, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Q3 2022 & Recent Highlights

- On track for topline **CLEAR Outcomes in January 2023**, with presentation targeted at ACC in March 2023
- U.S net product revenue of NEXLETOL® and NEXLIZET® recognized **growth of 28%** Y/Y to **$14** million in Q3 2022
- Retail Prescription Equivalents (RPE) grew **+2.4%** quarter over quarter
- Q3 2022 SG&A Expenses were down **36%** Y/Y
- Bempedoic acid recommended as **important oral non-statin therapy for LDL-cholesterol lowering by American College of Cardiology (ACC)** task force on expert consensus decision pathway
- Launched CLEAR Path 1 Pediatric Clinical Trial in patients 6-17 with heterozygous familial hypercholesterolemia
- Continued growth of our partner Daiichi Sankyo in their European territory
- Hosting R&D Day on November 9, 2022, to highlight pipeline programs featuring Global Scientific Leaders C. Michael Gibson, MS, MD (Harvard Medical Research Institutes) and Professor Peter Libby, MD (Brigham and Women's Hospital and Harvard Medical School)

Business Overview

Sheldon Koenig, President and CEO

Focus on Closing Out CLEAR Outcomes

Topline results January 2023

Global 14,014-patient randomized, double-blind, placebo-controlled clinical trial

- One of largest and longest of any non-statin trial; conducted in the modern-day medical environment

Unique patient population with high unmet need:

- Established ASCVD or at high-risk of developing ASCVD
- LDL-C ≥100 mg/dL on maximally-tolerated lipid-lowering therapy including no statin

Primary outcome (MACE-4): composite of the time to first cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization

Event-driven trial

- > 1,620 MACE-4 events achieved
- > 810 hard ischemic events (MACE-3) cardiovascular death, nonfatal myocardial infarction or nonfatal stroke achieved
- Median treatment duration of 3.5 years achieved

Financial Update

Sheldon Koenig, President and CEO

U.S. Revenue of $14.0 Million

Focused on driving consistent growth as we approach CVOT results

Quarterly Franchise RPE Trend



Weekly Franchise RPE Trend Since Launch [1]



1. Through September 30, 2022

*Based on Symphony data. RPE = Retail Prescription Equivalence; derived by normalizing the extended units Rx (no. of tablets) to determine the 30-day supply equivalent

Financial Strength to Deliver Growth

Cash runway sufficient beyond CLEAR Outcomes read-out

$14.0M Q3 2022 U.S. Product Revenue

$239M Q3 2022 Cash, Cash Equivalents, Restricted Cash & Investment Securities Available-for-Sale [1]

>$1.2B Potential Future Ex-U.S. Collaboration Milestones from Daiichi Sankyo & Otsuka

Key Financial Data

FY 2022 R&D Guidance	$100 - $110 Million
FY 2022 SG&A Guidance	$120 - $130 Million
FY 2022 Op Ex Guidance [2]	$220 - $240 Million
Q3 2022 Common Shares Outstanding [3]	71.7 Million

1. Includes $50M of restricted cash
2. Includes $25M of anticipated non-cash stock-based compensation expense
3. After accounting for 2.0 million treasury shares to be purchased in the $50M prepaid forward transaction as part of the November 2020 convertible debt financing

THANK YOU

ESPERION | REACHING GOALS

Important Safety Information

NEXLETOL® Safety Profile

- Contraindications: None
- Warnings and Precautions:
  - Hyperuricemia: NEXLETOL may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout.
  - Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture.
- Avoid concomitant use with simvastatin (>20 mg/day) or pravastatin (>40 mg/day) due to increased risk of adverse events.
- Most common adverse reactions in ≥2% of patients taking NEXLETOL and more frequently than placebo:
  - Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes
- Adverse events reported less frequently but still more often than in placebo included benign prostatic hyperplasia and atrial fibrillation

This summary does not reflect the full safety profile – please see https://pi.esperion.com/nexletol/nexletol-pi.pdf

NEXLIZET® Safety Profile

- Contraindication: Known hypersensitivity to ezetimibe tablets
- Warnings and Precautions:
  - Hyperuricemia: Bempedoic acid may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout.
  - Tendon Rupture: Bempedoic acid is associated with an increased risk of tendon rupture.
- Avoid concomitant use with simvastatin (>20 mg/day) or pravastatin (>40 mg/day). Monitor cyclosporine concentrations with cyclosporine. If cholelithiasis is suspected in a patient receiving fenofibrate, consider alternative lipid-lowering therapy.
- Most common adverse reactions in >2% of patients taking NEXLIZET and more frequently than placebo:
  - Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, elevated liver enzymes, diarrhea, fatigue, influenza, sinusitis, and arthralgia
- Adverse events reported less frequently but still more often than in placebo included benign prostatic hyperplasia and atrial fibrillation

This summary does not reflect the full safety profile - see https://pi.esperion.com/nexlizet/nexlizet-pi.pdf